The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

AgelessRx67 enrolled

Overview

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Aging

Interventions

RapamycinDRUG

Rapamycin in 2 different dosage forms (compounded and generic)

Eligibility

Sex: ALLMin age: 40 YearsMax age: 120 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Receive AgelessRx's standard Rapamycin treatment protocol * Opted to complete at least 1 blood draw at their local Quest Lab Exclusion Criteria: * Not approved for current AgelessRx standard Rapamycin treatment * History of uncontrolled disease * Unable to complete at least 1 blood draw at their local Quest Lab

Locations (1)

AgelessRx

Ann Arbor, Michigan, United States

Outcomes

Primary Outcomes

define the relative bioavailability ratio between compounded rapamycin and generic rapamycin

define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Time frame: 8 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.